medigraphic.com
ISSN 1527-3172 (Electronic)

2020, Number 4

<< Back Next >>

MEDICC Review 2020; 22 (4)

Levels of Vitamins and Homocysteine in Older Adults with Alzheimer Disease or Mild Cognitive Impairment in Cuba

Lanyau-Domínguez Y, Macías-Matos C, Llibre-Rodríguez JJ, Pita-Rodríguez GM, Suárez-Medina R, Quintero-Alejo ME, Noriega-Fernández L, Guerra-Hernández M, Calvo-Rodríguez M, Sánchez-Gil Y, García-Klibanski M, Herrera-Javier D, Arocha-Oriol C, Díaz-Domínguez M

Language: English
References: 49
Page: 40-47
PDF size: 166.17 Kb.


ABSTRACT

INTRODUCTION Age-related cognitive disorders, including Alzheimer disease, are among the main causes of disability and dependence in older adults worldwide. High blood homocysteine levels (hyperhomocysteinemia) are a risk factor for diseases whose metabolism involves different B vitamins. Antioxidant vitamins provide a protective effect by mitigating oxidative stress generated by these diseases. Epidemiological studies have presented varying results on the relationships between blood levels of these vitamins and such cognitive disorders.
OBJECTIVE Evaluate the association of vitamin and homocysteine levels with mild cognitive impairment and Alzheimer disease in a group of Cuban older adults.
METHODS A cross-sectional study was conducted in Havana, Cuba, of 424 persons aged ≥65 years: 43 with Alzheimer disease, 131 with mild cognitive impairment, and 250 with no signs of cognitive impairment. Dementia was diagnosed using criteria of the International 10/66 Dementia Research Group and Diagnostic and Statistical Manual of Mental Disorders (DSM IV), and mild cognitive impairment was diagnosed using Petersen’s criteria. Blood levels of vitamins (thiamine, B-2, folate, B-12, C and A) and homocysteine were measured by standard procedures. Analysis of variance for continuous variables and percentage comparison tests for dichotomous variables were used to compare groups.
RESULTS Persons with Alzheimer disease presented signifi cantly lower levels of vitamins B-2, C and A than healthy participants (p <0.05). Homocysteine levels were signifi cantly higher in those with Alzheimer disease and mild cognitive impairment than in participants with no cognitive impairment (p <0.05). Statistically, levels of thiamine, folic acid, and vitamin B-12 were not signifi cantly different across groups. Compared with those without cognitive impairment, prevalence rates (PR) in the Alzheimer group were signifi cantly higher for hyperhomocysteinemia (PR = 3.26; 1.84–5.80) and defi - ciency of all B vitamins: thiamine (PR = 1.89; 1.04–3.43), B-2 (PR = 2.85; 1.54–5.26), folate (PR = 3.02; 1.53–5.95), B-12 (PR = 2.21; 1.17–4.19), vitamin C (PR = 3.88; 2.12–7.10) and A (PR = 5.47; 3.26–9.17). In mild cognitive impairment, prevalence rates were signifi cantly higher for hyperhomocysteinemia (PR = 1.42; 1.08–1.87), vitamin B-2 defi ciency (PR = 1.70; 1.24–2.32) and vitamin A defi - ciency (PR =1.88; 1.05–3.38).
CONCLUSIONS Hyperhomocysteinemia and various vitamin defi ciencies are related to Alzheimer disease and mild cognitive impairment. Longitudinal studies are needed to further elucidate the relationship between different nutritional biomarkers and dementia. A better understanding of this relationship could provide a basis for therapeutic and preventive strategies.


REFERENCES

  1. World Health Organization [Internet]. Geneva: World Health Organization; c2019. Centro de prensa. Notas descriptivas. Demencia; 2019 Sep [cited 2019 Nov 10]; [about 4 screens]. Available at: https://www.who.int/es/news-room/fact -sheets/detail/dementia. Spanish.

  2. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70.

  3. Reymond AG, Gispert EA, Llibre JJ, Castell- Florit P, Bosch R I, Llerena T. Percepción de las demencias y la intersectorialidad en el contexto del Policlínico Docente Playa. Rev Cubana Salud Pública. 2019;45(1):e1128. Spanish.

  4. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2017 (Table 19). Havana: Ministry of Public Health (CU); 2018 Apr [cited 2020 Jun 2]. 206 p. Available at: https://fi les.sld.cu/dne /files/2018/04/Anuario-Electronico-Espa %c3%b1ol-2017-ed-2018.pdf. Spanish.

  5. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2018 (Table 19) [Internet]. Havana: Ministry of Public Health (CU); 2019 May [cited 2020 Jun 2]. 206 p. Available at: https://fi les.sld.cu/bvs cuba/files/2019/04/Anuario-Electr%c3%b3nico -Espa%c3%b1ol-2018-ed-2019-compressed.pdf Spanish.

  6. Vega JN, Newhouse PA. Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep. 2014 Oct;16(10):490. DOI: 10.1007/s11920 -014-0490-8.

  7. Prince M, Albanese E, Guerchet M, Prina M. Alzheimer’s Disease International. World Alzheimer Report 2014. Dementia and risk reduction. An analysis of protective and modifi - able factors. London: Alzheimer’s Disease International; 2014.

  8. Prina M, Albanese E. Nutritional factors and dementia prevention. In: Prince M, Albanese E, Guerchet M, Prina M, editors. Nutrition and Dementia: a review of available research. London: Alzheimer’s Disease International; 2014. p. 31–42.

  9. Smith D, Refsum H. Homocysteine, B Vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.

  10. Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifi able factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014 Jun 24;14:643.

  11. Shen L, Ji H. Associations between homocysteine, folic acid, vitamin B12 and Alzheimer’s disease: insights from meta-analyses. J Alzheimers Dis. 2015;46(3):777–90.

  12. Zaric B, Obradovic M, Bajic V, Haidara M, Jovanovic M, Isenovic E. Homocysteine and hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948–61.

  13. Baroni L, Bonetto C, Rizzo G, Bertola C, Caberlotto L, Bazzerla G. Asocciation between cognitive impairment and vitamin B12, folate, and homocysteine status in elderly adults: a retrospective study. J Alzheimer’s Dis. 2019 Jul 23;70(2):443–53.

  14. Robinson N, Grabowski P, Rehman I. Alzhemer’s disease pathogenesis: is there a role for folate? Mech Ageing Dev. 2018 Sep;174:86–94.

  15. Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: role in mild cognitive impairment, dementia and depression. Ageing Res Rev. 2015 May;22:9–19.

  16. O’Leary F, Allman M, Samman S. Vitamin B12 status, cognitive impairment and dementia: a systematic review of prospective cohort studies. British J Nutr. 2012 Dec 14;108(11):1948– 61.

  17. von Arnim CA, Herbolsheimer F, Nikolaus T, Peter R, Biesalski HK, Ludolph AC, et al. Dietary antioxidants and dementia in a populationbased case-control study among older people in South Germany. J Alzheimers Dis. 2011 Dec 31;31(4):717–24.

  18. Lanyau Domínguez Y, Hernández M, Macías Matos C, Zhou D. Is B vitamins defi ciency associated with prevalence of Alzheimer’s disease in Cuban elderly? Nutr Health. 2006 Jan 1;18(2):103–18.

  19. Gónzález L. Reforma económica en Cuba: mecanismos de desigualdad social y su repercusión en las personas de la Tercera Edad. INFOHEM. 2016;14(2):20–7. Spanish.

  20. Llibre Rodríguez JJ, Valhuerdi Cepero A, Calvo M, García RM, Guerra M, Laucerique T, et al. Dementia and other chronic diseases in older adults in Havana and Matanzas: The 10/66 study in Cuba. MEDICC Rev. 2011 Oct;13(4):30–7.

  21. Llibre Rodríguez JJ, Valhuerdi Cepero A, López Medina AM, Noriega Fernández L, Porto Álvarez R, Guerra Hernández MA, et al. Cuba’s aging and Alzheimer longitudinal study. MEDICC Rev. 2017 Jan;19(1):31–5.

  22. Copeland JR, Dewey ME, Griffi th-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med. 1986 Jan 31;16(1):89–99.

  23. Hall KS, Hendrie HH, Brittain HM, Norton JA, Rodgers DD, Prince CS, et al. The development of a dementia screening interview in two distinct languages. Int J Methods Psychiatric Res. 1993;3:1–28.

  24. Ganguli M, Chandra V, Gilbey JE, Ratcliff G, Sharma SD, Pandav R, et al. Cognitive test performance in a community-based non demented elderly sample in rural India: the Indo-US cross national dementia epidemiology study. Int Psychogeriatr. 1996 Winter;8(4):507–24.

  25. Dewey ME, Copeland JR. Diagnosis of dementia from the history and aetiology schedule. Int J Geriatr Psychiatry. 2001 Sep;16(9):912–7.

  26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, D.C.: American Psychiatry Association; 1994 Jan 15. 886 p.

  27. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence- based review). Report of the Quality Standards Subcommittee of the American Academy Neurology. Neurology. 2001 May 8;56(9):1133–42.

  28. Van Den Berg H, Heseker H, Lamand M, Sandstrom B, Thurnham D. Flair Concerted Action No 10 Status Papers. Int J Vit Nutr Res. 1993;63:247–316.

  29. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39(9):1764–79.

  30. Interdepartmental Committee on Nutrition for National Defense; National Institutes of Health. Serum Vitamin C (Ascorbic Acid)-Dinitrophenyl hydrazine method. In: Manual for Nutrition Surveys. 2nd ed. Washington, D.C.: Interdepartmental Committee on Nutrition for National Defense; 1963. p. 117–9.

  31. Thurnham DI, Smith E, Flora PS. Current Liquid- Chromatographic assay of retinol, alfa-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxantin in plasma with tocopherol acetate as internal standard. Clin Chem. 1988;43:377–81.

  32. Fidanza F. Nutritional Status Assessment. A manual for population studies. New York: Chapman & Hall; 1991. p. 228–309.

  33. Basu TK, Patel DR, Williams DC. A simplifi ed microassay of transketolase in human blood. Int J Vit Res. 1974;44:319–26.

  34. Selhub J, Jacques PF, Dallal G, Choumenkovitch S, Rogers G. The use of blood concentrations of vitamins and their respective functional indicators to defi ne folate and vitamin B12 status. Food & Nutr Bull. 2008;29:567–73.

  35. World Medical Association [Internet]. Ferney- Voltaire (FR): World Medical Association; c2020. Políticas. Políticas actuales. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos; 2017 Mar 21 [cited 2012 Nov 18]. Available at: https://www.wma.net/es/ policies-post/declaracion-de-helsinki-de-la-amm -principios-eticos-para-las-investigaciones-medi cas-en-seres-humanos/. Spanish.

  36. Smith D, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, et al. Homocysteine and Dementia: An International Consensus Statement. J Alzheimer’s Dis. 2018;62:561–70.

  37. Sharma M, Tiwart M, Kumar RK. Hyperhomocysteinemia: impact on neurodegenerative diseases. Basis & Clin Pharmacol & Toxicol. 2015;117(5):287–96.

  38. Porter K, Hoey L, Hughes C, Ward M, McNulty H. Causes, consequences and public health. Implications of low B-Vitamin status in ageing. Nutrients. 2016;8:725. DOI: 10.3390.

  39. Lopes da Silva S, Vellas B, Elemans S, Luchsinger J, Kamphuis P, Yaffe K, et al. Plasma nutrient status of patients with Alzheimer’s disease: systematic review and meta-analysis. Alzheimer’s & Dementia. 2013:1–18.

  40. Kim G, Kim H, Kim KN, Son JI, Kim SY, Tamura T, et al. Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross sectional survey. J Alzheimers Dis. 2013;33(3):853–62.

  41. Faux N, Ellis K, Porter L, Fowler C, Laws S, Martins R, et al. Homocysteine, vitamin B12, and Folic acid levels in Alzheimer’s disease, Mild Cognitive Impairment, and Healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimer’s Dis. 2011;27(4):909–22.

  42. Ma F, Wu T, Zhao J, Ji L, Song A, Zhang M, et al. Plasma homocysteine and serum folate and vitamin B12 levels in Mild Cognitive Impairment and Alzheimer’s Disease: a case-control study. Nutrients. 2017;9(7):pii:E725. DOI:10.3390/ nu9070725.

  43. Meng H, Li Y, Zhang W, Zhao Y, Niu X, Guo J. The relationship between cognitive impairment and homocysteine in a B12 and folate defi cient population in China: a cross- sectional study. Medicine (Baltimore). 2019;98(47):el7970.

  44. Hyesook K, Ggotpin K, Wong J, Seong Y, Namsoo C. Association between intake of B vitamins and cognitive function ibn elderly Koreans with cognitive impairment. Nutrition J. 2014;13:118.

  45. Vinhquoc K, Thi Hoáng L. Role of Thiamine in Alzheimer’s Disease. Am J Alzheimer’s Dis & Other Dementias. 2011;26 (8):588–98.

  46. Hazell A, Faim S, Wertheimer G, Silva V, Marques C. The impact of oxidative stress in thiamine defi ciency: a multifactorial targeting issue. Neurochem Int. 2013;62:796–802.

  47. de Wilde M, Vellas B, Girault E, Cetinyurek Yavuz A, Sijben JW. Lower brain and blood nutrient status in Alzheimer’s disease: results from meta-analyses. Alzheimer Dement. 2017 Sep;3(3):416–31.

  48. Hyeok J, Lee H, Min Lee K. The possible role of antioxidant vitamin C in Alzheimer’s disease treatment and prevention. Am J Alzheimer’s Dis & Other Dementias. 2013;28(2):120–5.

  49. Ono K, Yamada M. Vitamin A and Alzheimer’s disease. Geriatr Gerontol. 2012;12:180–8.




2020     |     www.medigraphic.com